WO2003037159A3 - An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease - Google Patents

An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease Download PDF

Info

Publication number
WO2003037159A3
WO2003037159A3 PCT/US2002/033353 US0233353W WO03037159A3 WO 2003037159 A3 WO2003037159 A3 WO 2003037159A3 US 0233353 W US0233353 W US 0233353W WO 03037159 A3 WO03037159 A3 WO 03037159A3
Authority
WO
WIPO (PCT)
Prior art keywords
albuterol
kit
solution
pulmonary disease
chronic obstructive
Prior art date
Application number
PCT/US2002/033353
Other languages
French (fr)
Other versions
WO2003037159A2 (en
Inventor
Imtiaz Chaudry
Partha Banerjee
Original Assignee
Dey L P
Imtiaz Chaudry
Partha Banerjee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU32974/02A priority Critical patent/AU3297402A/en
Priority claimed from JP2002158304A external-priority patent/JP2003221335A/en
Application filed by Dey L P, Imtiaz Chaudry, Partha Banerjee filed Critical Dey L P
Priority to EP02789216A priority patent/EP1446045A4/en
Priority to CNA2006101077523A priority patent/CN1939279A/en
Priority to JP2003539509A priority patent/JP2006505486A/en
Priority to CA2464735A priority patent/CA2464735C/en
Priority to MXPA04003927A priority patent/MXPA04003927A/en
Priority to US10/417,726 priority patent/US20030191151A1/en
Publication of WO2003037159A2 publication Critical patent/WO2003037159A2/en
Publication of WO2003037159A3 publication Critical patent/WO2003037159A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.
PCT/US2002/033353 2001-10-26 2002-10-18 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease WO2003037159A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU32974/02A AU3297402A (en) 2001-10-26 2002-04-05 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
EP02789216A EP1446045A4 (en) 2001-10-26 2002-10-18 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
CNA2006101077523A CN1939279A (en) 2001-10-26 2002-10-18 Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003539509A JP2006505486A (en) 2001-10-26 2002-10-18 Albuterol and ipratropium inhalation solutions, systems, kits and methods for alleviating symptoms of chronic obstructive pulmonary disease
CA2464735A CA2464735C (en) 2001-10-26 2002-10-18 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
MXPA04003927A MXPA04003927A (en) 2001-10-26 2002-10-18 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease.
US10/417,726 US20030191151A1 (en) 2001-10-26 2003-04-15 Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US34607801P 2001-10-26 2001-10-26
US60/346,078 2001-10-26
US3465701A 2001-12-28 2001-12-28
US10/034,657 2001-12-28
AU32974/02 2002-04-05
AU32974/02A AU3297402A (en) 2001-10-26 2002-04-05 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2002-158304 2002-04-23
JP2002158304A JP2003221335A (en) 2001-10-26 2002-04-23 Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
WO2003037159A2 WO2003037159A2 (en) 2003-05-08
WO2003037159A3 true WO2003037159A3 (en) 2003-10-16

Family

ID=27422968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033353 WO2003037159A2 (en) 2001-10-26 2002-10-18 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease

Country Status (8)

Country Link
EP (1) EP1446045A4 (en)
JP (1) JP2006505486A (en)
CN (2) CN1607940A (en)
AU (1) AU3297402A (en)
CA (1) CA2464735C (en)
MX (1) MXPA04003927A (en)
NZ (1) NZ552548A (en)
WO (1) WO2003037159A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915985A1 (en) * 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
US20070276048A1 (en) * 2006-05-18 2007-11-29 Verus Pharmaceuticals, Inc. Unit dose formulations comprising an inhalable solution of albuterol
WO2007134965A1 (en) * 2006-05-19 2007-11-29 Boehringer Ingelheim International Gmbh Aerosol formulation containing ipratropium bromide and salbutamol sulfate
JP5317961B2 (en) * 2006-05-19 2013-10-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhalation aerosol formulation containing ipratropium bromide and salbutamol sulfate without propellant
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
EP2414560B1 (en) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Method for coating a surface of a component
WO2010133294A2 (en) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and atomizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
MX2012005961A (en) 2009-11-25 2012-06-14 Boehringer Ingelheim Int Nebulizer.
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
EP4059499A1 (en) * 2011-01-31 2022-09-21 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2694220B1 (en) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
JP6643231B2 (en) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
PL2835146T3 (en) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizer
CA2930173A1 (en) * 2013-11-22 2015-05-28 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable medicament
DK2897589T3 (en) 2013-11-22 2018-03-12 Teva Branded Pharmaceutical Prod R & D Inc Inhalable drug
ES2874029T3 (en) 2014-05-07 2021-11-04 Boehringer Ingelheim Int Nebulizer
EP3139979B1 (en) 2014-05-07 2023-07-05 Boehringer Ingelheim International GmbH Unit, nebulizer and method
MX2016014399A (en) 2014-05-07 2017-01-20 Boehringer Ingelheim Int Nebulizer.
CN106344544A (en) * 2016-08-25 2017-01-25 杭州百诚医药科技股份有限公司 Aerosol inhalation preparation for treating bronchial asthma
CN110898042B (en) * 2019-12-12 2020-10-16 深圳大佛药业股份有限公司 Salbutamol sulfate solution for inhalation and preparation method thereof
CN111053761B (en) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 Bisphosphonic acid medicine for inhalation, preparation method thereof and application thereof in chronic obstructive pulmonary disease
CN115209872A (en) * 2020-03-19 2022-10-18 广州谷森制药有限公司 Inhalable formulations containing levosalbutamol tartrate
CN113018280A (en) * 2021-03-01 2021-06-25 石家庄四药有限公司 Solution preparation for ipratropium bromide inhalation and preparation method thereof
CN115645381B (en) * 2022-10-20 2023-05-30 深圳大佛药业股份有限公司 Levalmol hydrochloride aerosol inhalation solution sustained release agent and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6247617B1 (en) * 1999-12-13 2001-06-19 Richard Allen Clyde Single use container for dispensing separately housed sterile compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69324161T2 (en) * 1992-12-09 1999-10-28 Boehringer Ingelheim Pharma STABILIZED MEDICAL AEROSOL SOLUTIONS
DE19653969A1 (en) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg New aqueous pharmaceutical preparation for the production of propellant-free aerosols

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6247617B1 (en) * 1999-12-13 2001-06-19 Richard Allen Clyde Single use container for dispensing separately housed sterile compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Combivent data sheet, information for health professional", BOEHRINGER INGELHEIM (N.Z.) LIMITED, 25 March 1999 (1999-03-25), pages 1 - 8, XP002967584, Retrieved from the Internet <URL:www.medsafe.govt.rz> *
GROSS ET AL.: "Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease", RESPIRATION, vol. 65, 1998, pages 354 - 362, XP008103328 *
See also references of EP1446045A4 *

Also Published As

Publication number Publication date
WO2003037159A2 (en) 2003-05-08
CN1939279A (en) 2007-04-04
CN1607940A (en) 2005-04-20
NZ552548A (en) 2009-03-31
MXPA04003927A (en) 2005-03-31
EP1446045A2 (en) 2004-08-18
AU3297402A (en) 2003-10-30
EP1446045A4 (en) 2010-07-21
CA2464735A1 (en) 2003-05-08
CA2464735C (en) 2011-03-22
JP2006505486A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2003037159A3 (en) An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
WO2003024433A3 (en) Compositions for treatment of common cold, comprising ipratropium and xylometazoline
WO2003013434A3 (en) Methods and compositions for treating diseases associated with excesses in ace
AU5900601A (en) Novel process
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
MY129512A (en) Novel medicament compositions, based on tiotropium bromide and salmeterol
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
WO2004091536A3 (en) An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
AU2002316935A1 (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases
AU2001252192A1 (en) Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd)
WO2006133374A3 (en) Methods for treating shock
WO2000066107A3 (en) Antimalarian agents for the treatment of asthma
GB2383041A (en) Process for the preparation of gabapentin
SE9900833D0 (en) Novel combination
MXPA03011702A (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases.
WO2002072086A8 (en) Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
WO2002065989A3 (en) Aminoglycoside treatment for lysosomal storage diseases
SE9900834D0 (en) Novel combination
WO2002072104A3 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2000056345A3 (en) Methods for limiting scar and adhesion formation
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
WO2001068069A3 (en) Pharmaceutical composition comprising paracetamol
WO2004105759A3 (en) Novel long-acting medicament combinations comprising an anticholinergic agent and a $g(b)2-adrenoreceptor antagonist for the treatment of respiratory tract diseases
CA2358840A1 (en) Methods and kits comprising an estrogen agonist/antagonist for improving vascular health

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2003539509

Country of ref document: JP

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2464735

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003927

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 532973

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002353825

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2002789216

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002789216

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028262263

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002789216

Country of ref document: EP